Kimberly Smith spent thirty years inside the HIV epidemic. The last thirteen of them were spent trying to make the drugs that ended it faster.
Smith, ViiV Healthcare's Head of Research and Development, is retiring, Endpoints News reported Monday, citing the change and naming Charlotte Allerton — a Pfizer executive and member of ViiV's board of directors whose work includes co-leading the discovery of Paxlovid — as her successor. ViiV and GSK have not independently confirmed the timing or the succession. What the public record supports is Smith's tenure and what she built. The rest is Endpoints's reporting, unverified by the company at time of publication.
ViiV Healthcare, 78.3 percent owned by GSK with the remaining 21.7 percent held by Shionogi, is the only pharmaceutical company structured entirely around HIV. The ownership shifted in January 2026 when Pfizer exited and Shionogi took its stake — a transaction that left ViiV with a cleaner cap table and a larger Japanese partner with ambitions in antiviral drugs. In that context, Smith's tenure is measured in specific drugs. Cabenuva, the twice-monthly or monthly injectable HIV treatment co-developed with Johnson & Johnson, generated £1.3 billion in sales in 2024, according to GSK's annual report. Dovato, the two-drug oral regimen, is the backbone of ViiV's oral franchise. Juluca, the first complete single-tablet two-drug regimen, was the proof of concept. Apretude, the long-acting injectable PrEP option requiring dosing every two months, was the market expansion. These are the products that define ViiV's commercial position and the pipeline Smith oversaw.
The long-acting platform is where the legacy is most legible. Cabenuva's every-other-monthly dosing data — showing non-inferiority to daily oral therapy — represents years of clinical development. Apretude's every-two-months PrEP profile, approved in 2021, positioned ViiV ahead of oral PrEP in a market where adherence is the central problem. Both require clinical infrastructure, clinician training, and patient willingness to inject. Both represent a bet that the future of HIV treatment is injectables, not pills. That bet is now the company's to execute — or revise.
The competitive environment has shifted. Gilead's lenacapavir, a twice-yearly injectable, entered the PrEP market with a dosing convenience advantage ViiV's products cannot match on frequency. Lenacapavir received FDA approval in June 2025 and demonstrated near-total prevention in cisgender women in the PURPOSE 1 trial — 100 percent efficacy — before expanding to broader populations. Those numbers landed inside ViiV's planning cycles differently — lenacapavir's twice-yearly dosing is a frequency advantage ViiV's monthly products cannot match right now.
Allerton brings a discovery background. Her work at Pfizer includes co-leading the discovery and development of Paxlovid — a credential that signals a different kind of ambition than HIV-specific drug development. She sits on ViiV's board of directors, which means she has been close to the company's planning for some time. Whether that planning culminates in a long-acting platform expansion, a mechanistic pivot, or a competitive response to lenacapavir depends in part on whether the succession Endpoints reported actually plays out as described.
What Smith built is real. The injectable HIV franchise did not exist before ViiV built it. Whether that market continues to expand or whether Gilead's twice-yearly drug changes the competitive calculus is a question the next R&D head will answer first — assuming the succession confirms.
